Results 71 to 80 of about 6,510 (202)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

Nature Communications, 2023
Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization.
Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, Amirhossein Karimi, Nicole A. P. Lieberman, Zachary M. Sticher, Pavitra Roychoudhury, Meghan K. Andrews, Rebecca E. Krueger, Michael G. Natchus, George R. Painter, Alexander A. Kolykhalov, Alexander L. Greninger, Richard K. Plemper   +13 more
doaj   +1 more source

Post‐COVID‐19 Area Postrema Syndrome With SARS‐CoV‐2 in CSF: A Dual‐Case Report and Review of the Literature

Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.
This dual‐case report describes two patients with post‐COVID‐19 area postrema syndrome whose outcomes were dictated by their AQP4‐IgG serostatus, despite both having SARS‐CoV‐2 detected in their CSF. The stark contrast between the seronegative patient's recovery and the seropositive patient's fatal relapse highlights antibody testing as an urgent and ...
Wan Zhu, Jing Qian, Min Peng, Yan Li, Jinghan Hu   +4 more
wiley   +1 more source

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Frequency and Duration of the Clinical Symptoms of Patients With Mild COVID‐19: A Comparison With Influenza in the 2023–2024 Japanese Influenza Season, an Observational Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims This study aimed to compare the clinical symptoms of mild COVID‐19 and influenza during a period when both diseases circulated in the 2023–2024 influenza season in Japan. Methods Outpatients diagnosed with COVID‐19, influenza A, or influenza B by antigen test kits at 10 medical facilities in Japan were enrolled.
Takuma Bando, Hideyuki Ikematsu, Naoki Kawai, Tetsunari Maeda, Woon Joo Lee, Shinro Matsuura, Osame Tanaka, Takashi Kawashima, Hareaki Yamamoto, Ietaka Sato, Ken‐ichi Doniwa   +10 more
wiley   +1 more source

A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments [PDF]

Objective: Unusual clinical course Background: SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment.
Cingolani, Antonella, Del Giacomo, Paola, Innocenti, Idanna, Laurenti, Luca, Leanza, Gabriele Maria, Liotti, Flora Marzia, Magrini, Eugenia, Maiuro, Giuseppe, Santangelo, Rosaria   +8 more
core   +1 more source

Reduced Mortality in COVID‐19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24

Journal of Extracellular Vesicles, Volume 15, Issue 3, March 2026.
ABSTRACT Background: Severe COVID‐19, and other systemic infections, can trigger hyperinflammation leading to lung injury. EXO‐CD24, an inhaled extracellular vesicle therapy with anti‐inflammatory properties, has shown acute clinical benefit, but long‐term effects on survival remain unknown.
Shiran Shapira, Guy Vishnevsky, Hadas Yaakobi, Gil Shenberg, Mays Motlaq, Eliezer Liberman, Aminadav Kalisky, Gadi Benari, Sotirios Tsiodras, Nimrod Adi, Jan Lötvall, Nadir Arber   +11 more
wiley   +1 more source

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients

Scientific Reports
Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain.
Fatemeh Saheb Sharif-Askari, Hawra Ali Hussain Alsayed, Narjes Saheb Sharif-Askari, Ali Al Sayed Hussain, Saleh Al-Muhsen, Rabih Halwani   +5 more
doaj   +1 more source

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

Journal of Cardiothoracic Surgery
Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients.
Chien-Ming Lo, Wei-Hsun Chen, Meng-Yun Tsai, Hung-I Lu, Yu-Hsin Hsiao, Kai-Hao Chuang, Yu Chen, Hsuan-Feng Wu, Kuo-Tung Huang, Yi-Hsi Wang   +9 more
doaj   +1 more source

Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Nature Communications
Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection.
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Sophelia H. S. Chan, Eric H. Y. Lau, Benjamin J. Cowling, Gabriel M. Leung   +6 more
doaj   +1 more source